Transcatheter aortic valve replacement in patients with extremely severe aortic stenosis. 2021

Mike Saji, and Ryosuke Higuchi, and Yuki Izumi, and Itaru Takamisawa, and Nobuo Iguchi, and Mamoru Nanasato, and Jun Shimizu, and Tomoki Shimokawa, and Shuichiro Takanashi, and Morimasa Takayama, and Mitsuaki Isobe
Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. Electronic address: mikesaji8@gmail.com.

Although most patients with severe aortic stenosis (AS) have high aortic valve velocities, outcomes of transcatheter aortic valve replacement (TAVR) in patients with extremely high aortic valve velocities remain unclear. We aimed to investigate the clinical outcomes of patients with peak aortic jet velocity (Vmax) values ≥ 6 m/s. The study included 913 consecutive patients who underwent TAVR between 2013 and 2020. To better understand the impacts of the higher Vmax on outcomes, patients with Vmax values < 4.0 m/s, ejection fractions < 50%, valve-in-valve procedures, and unstable hemodynamics were excluded. Patients were grouped according to preprocedural Vmax as follows: 4-5 m/s, 5-6 m/s, and ≥ 6 m/s. According to guidelines describing Vmax ≥ 5.0 m/s as "very" severe AS, Vmax ≥ 6.0 m/s was defined as "extremely" severe AS in this study. New York Heart Association classification-III/IV and severe left ventricular hypertrophy were more frequent in the extremely severe AS group, which concurred with the advanced stage of severe AS, and they had a similar mortality rate to the other groups. Although they showed the greatest Vmax improvements after TAVR, they had higher paravalvular leak (PVL) rates. Even among the patients who received newer-generation transcatheter aortic valves, they had higher PVL rates, despite more frequent balloon dilation than the other groups. Although patients with extremely severe AS have similar mortality rates to other patients with severe AS after TAVR, the risk of procedural complications caused by more frequent balloon dilation should be considered.

UI MeSH Term Description Entries
D006350 Heart Valve Prosthesis A device that substitutes for a heart valve. It may be composed of biological material (BIOPROSTHESIS) and/or synthetic material. Prosthesis, Heart Valve,Cardiac Valve Prosthesis,Cardiac Valve Prostheses,Heart Valve Prostheses,Prostheses, Cardiac Valve,Prostheses, Heart Valve,Prosthesis, Cardiac Valve,Valve Prostheses, Cardiac,Valve Prostheses, Heart,Valve Prosthesis, Cardiac,Valve Prosthesis, Heart
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001021 Aortic Valve The valve between the left ventricle and the ascending aorta which prevents backflow into the left ventricle. Aortic Valves,Valve, Aortic,Valves, Aortic
D001024 Aortic Valve Stenosis A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA. Aortic Stenosis,Aortic Valve Stenoses,Stenoses, Aortic,Stenoses, Aortic Valve,Stenosis, Aortic,Stenosis, Aortic Valve,Valve Stenoses, Aortic,Valve Stenosis, Aortic
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D065467 Transcatheter Aortic Valve Replacement Surgical treatment for severe AORTIC VALVE STENOSIS. Transcatheter aortic valve replacement (TAVR) is used as an alternative option in patients who are deemed at high risk or inoperable for traditional open-heart surgery. Transcatheter Aortic Valve Implantation

Related Publications

Mike Saji, and Ryosuke Higuchi, and Yuki Izumi, and Itaru Takamisawa, and Nobuo Iguchi, and Mamoru Nanasato, and Jun Shimizu, and Tomoki Shimokawa, and Shuichiro Takanashi, and Morimasa Takayama, and Mitsuaki Isobe
January 2019, JACC. Cardiovascular interventions,
Mike Saji, and Ryosuke Higuchi, and Yuki Izumi, and Itaru Takamisawa, and Nobuo Iguchi, and Mamoru Nanasato, and Jun Shimizu, and Tomoki Shimokawa, and Shuichiro Takanashi, and Morimasa Takayama, and Mitsuaki Isobe
July 2019, Zhonghua xin xue guan bing za zhi,
Mike Saji, and Ryosuke Higuchi, and Yuki Izumi, and Itaru Takamisawa, and Nobuo Iguchi, and Mamoru Nanasato, and Jun Shimizu, and Tomoki Shimokawa, and Shuichiro Takanashi, and Morimasa Takayama, and Mitsuaki Isobe
June 2020, American heart journal,
Mike Saji, and Ryosuke Higuchi, and Yuki Izumi, and Itaru Takamisawa, and Nobuo Iguchi, and Mamoru Nanasato, and Jun Shimizu, and Tomoki Shimokawa, and Shuichiro Takanashi, and Morimasa Takayama, and Mitsuaki Isobe
December 2023, Revista espanola de cardiologia (English ed.),
Mike Saji, and Ryosuke Higuchi, and Yuki Izumi, and Itaru Takamisawa, and Nobuo Iguchi, and Mamoru Nanasato, and Jun Shimizu, and Tomoki Shimokawa, and Shuichiro Takanashi, and Morimasa Takayama, and Mitsuaki Isobe
January 2014, Critical care nursing quarterly,
Mike Saji, and Ryosuke Higuchi, and Yuki Izumi, and Itaru Takamisawa, and Nobuo Iguchi, and Mamoru Nanasato, and Jun Shimizu, and Tomoki Shimokawa, and Shuichiro Takanashi, and Morimasa Takayama, and Mitsuaki Isobe
April 2019, JAMA,
Mike Saji, and Ryosuke Higuchi, and Yuki Izumi, and Itaru Takamisawa, and Nobuo Iguchi, and Mamoru Nanasato, and Jun Shimizu, and Tomoki Shimokawa, and Shuichiro Takanashi, and Morimasa Takayama, and Mitsuaki Isobe
January 2016, The American journal of cardiology,
Mike Saji, and Ryosuke Higuchi, and Yuki Izumi, and Itaru Takamisawa, and Nobuo Iguchi, and Mamoru Nanasato, and Jun Shimizu, and Tomoki Shimokawa, and Shuichiro Takanashi, and Morimasa Takayama, and Mitsuaki Isobe
April 2022, JACC. Asia,
Mike Saji, and Ryosuke Higuchi, and Yuki Izumi, and Itaru Takamisawa, and Nobuo Iguchi, and Mamoru Nanasato, and Jun Shimizu, and Tomoki Shimokawa, and Shuichiro Takanashi, and Morimasa Takayama, and Mitsuaki Isobe
November 2018, Heart failure reviews,
Mike Saji, and Ryosuke Higuchi, and Yuki Izumi, and Itaru Takamisawa, and Nobuo Iguchi, and Mamoru Nanasato, and Jun Shimizu, and Tomoki Shimokawa, and Shuichiro Takanashi, and Morimasa Takayama, and Mitsuaki Isobe
October 2018, Journal of the American College of Cardiology,
Copied contents to your clipboard!